(e.g., ISO 13485)

Table: Key Parameters for Analytical Validation

Validation Parameter	Target Criteria
LOD	<1 ng/mL or as clinically relevant
Precision (%CV)	<15% for intra-assay, <20% for inter-assay
Linearity (r²)	≥0.98
Stability	Validated at room temp, 2–8°C, -20°C

These parameters are non-negotiable for a PMA (FDA) or CE marking (EMA). Real-world evidence and post-marketing surveillance are also becoming important, especially for oncology biomarkers like PD-L1 and HER2.

FDA Regulatory Framework and Submission Pathway

The FDA treats companion diagnostics as Class III devices, requiring Premarket Approval (PMA). A biomarker must be co-developed with the therapeutic product or undergo a bridging study if developed independently.

• PMA includes:
• Design history file (DHF)
• Analytical validation report
• Clinical trial data (from pivotal or bridging studies)
• Labeling: Intended use, specimen type, interpretation, cut-offs

FDA’s Center for Devices and Radiological Health (CDRH) and Center for Drug Evaluation and Research (CDER) collaborate on biomarker reviews. Early interaction via Pre-Submission (Q-Sub) is encouraged to align expectations. Visit PharmaSOP.in for FDA-ready SOP templates.

EMA’s Companion Biomarker Review Process

The EMA oversees CDx validation as part of the overall drug approval process under the EU IVD Regulation (IVDR). A notified body evaluates the device separately while the EMA Committee for Medicinal Products for Human Use (CHMP) assesses the drug.

Requirements include:

• Technical documentation (per IVDR Annexes II and III)
• Scientific validity report
• Risk-benefit analysis
• Performance evaluation report (PER)
• EU Declaration of Conformity

The biomarker must demonstrate analytical performance across multiple populations, especially for pan-European use. EMA supports rolling review and scientific advice meetings during development to avoid delays.

Bridging Studies and Post-Approval Commitments

When a diagnostic is introduced after the drug’s pivotal study, bridging studies become essential. These studies link retrospective or prospective data from the approved therapeutic trial to the new diagnostic.

• Requirements:
• Concordance studies with original test
• Re-testing of archived trial samples
• Statistical comparison (e.g., kappa coefficient, McNemar’s test)

Case Example: A TMB assay was introduced after Phase III trials for a checkpoint inhibitor. Bridging was performed on 300 archived samples. FDA accepted a concordance rate of 92% with the original NGS assay.

Post-approval, FDA and EMA may require ongoing surveillance, proficiency testing, and label updates if new populations or indications emerge.

Labeling and Intended Use Considerations

Both agencies require precise labeling of the companion diagnostic to reflect:

• Drug name and indication
• Cut-off values and interpretation
• Sample type (e.g., FFPE tissue, whole blood)
• Assay limitations (e.g., interferences, equivocal zone)

FDA’s format must follow 21 CFR Part 809.10, while EMA aligns with IVDR Annex I. Any discrepancy between trial and marketed versions must be justified and explained.

Clinical Utility and Evidence Requirements

Demonstrating clinical utility—the ability of the biomarker to improve clinical outcomes—is increasingly critical. Regulatory bodies now require data linking biomarker presence to patient benefit.

• Subgroup analysis from pivotal trials (e.g., PD-L1 high vs low)
• Hazard ratios, AUC, and net reclassification index (NRI)
• Predictive vs prognostic marker differentiation

Example: For EGFR mutation detection in NSCLC, both FDA and EMA required survival benefit data for EGFR-positive vs negative cohorts stratified by diagnostic test result.

Risk-Based Approach to Validation

FDA and EMA adopt a risk-based approach. If a diagnostic error could lead to serious harm (e.g., false negative for life-saving treatment), the validation rigor is high. Risk classification impacts documentation, review time, and approval burden.

Risk factors:

• Impact on clinical decision
• Novel technology vs established method
• Therapeutic window and indication severity

Low-risk biomarkers may follow 510(k) pathways in the U.S. or Class B classification in the EU, while CDx linked to oncology or rare diseases are often Class III or Class D respectively.

Emerging Regulatory Trends

Recent trends shaping biomarker validation include:

• Digital pathology and AI-enabled diagnostics
• Multiplex panels requiring cross-reactivity testing
• Use of real-world evidence for validation
• Global harmonization through ICH guidelines

Regulators are also pushing for early consultation during drug development to align biomarker strategy with trial endpoints and commercial plans.

Conclusion

Validating a companion biomarker requires not only scientific rigor but also regulatory foresight. Both FDA and EMA emphasize analytical precision, clinical relevance, and submission readiness. A successful validation strategy includes early planning, clear labeling, robust documentation, and proactive dialogue with regulators. With the right approach, biomarker developers can accelerate approvals, expand indications, and deliver personalized therapies that truly make a difference.